It is extensively documented that tumor hypoxia contributes to the failure of chemotherapy and radiotherapy. Recent evidence suggests that hypoxia is also closely involved in the resistance to immunotherapy. In this review, we highlight how immune cells that are essential for the maximized immunotherapy efficacy, including cytotoxic T cells, dendritic cells, and natural killer cells, can adapt to tumor hypoxia. We then outline previous attempts targeting tumor hypoxia (for example, modulators of tumor cell oxygen consumption, perfusion modulators, hypoxia-activated prodrugs, hypoxia-inducible factor inhibitors, and hypoxia-responsive chimeric antigen receptor T cells) discussing how these approaches have resulted in an improvement of the antitumor response to immunotherapy in preclinical or clinical settings. Lastly, we review various non-invasive techniques to detect the tumor hypoxia and immune responses. We believe that an integration of the biological knowledge of immune cell adaptation to tumor hypoxia with the cutting edge non-invasive imaging technologies may ultimately allow us not only to select for patients who would benefit the most from the immunotherapy but also to monitor their responses in a real-time manner so that we can offer them an optimal personalized medicine in the clinic.
Citations
Citations to this article as recorded by
Fucoidans as multifunctional marine polysaccharide platforms: From nutritional supplements to advanced drug delivery for cancer therapy Yuning Liu, Lin Long, Jianhua Zang, Chuanlong Guo, Jun Xiao, Gaoyang Lin International Journal of Pharmaceutics: X.2026; 11: 100546. CrossRef
Heterogeneity, Measurement, and Clinical Implications of Oxygenation, Cell Signaling, and Redox Biology in Glioblastoma and Adult Diffuse Gliomas, with Context from Other Brain Tumors Arabinda Das, Julian E. Bailes, Ann Barlow, Daniil P. Aksenov Antioxidants.2026; 15(4): 505. CrossRef
Bacterial-based cancer therapy: mechanisms and therapeutic advances Arman H. Sharifi, Ngoc Hai Trieu Phong, Anjali Marek, Mohammed A. Kamal, Suendus Al-Kodmany, Duy Binh Tran, Tohru Yamada Molecular Biomedicine.2026;[Epub] CrossRef
Immunomodulatory Nanozymes as Programmable Redox–Immune Set‐Point Regulators Sumi Choi, Minjeong Kim, Sang Jin Lee, Su‐Hwan Kim Small.2026;[Epub] CrossRef
Rationally
Designed Ru(II) Complex with Dual Type
I/II ROS Generation for Hypoxia-Tolerant Photodynamic Therapy in Melanoma Xueling Li, Yue Zhang, Yan Huang, Weixia Qing, Yong Wang, Pengtao Ma Inorganic Chemistry.2026; 65(40): 23983. CrossRef
Radioimmunotherapy: Mechanisms, Strategies, and Advances in Therapeutic Enhancement Syed Ali Raza Naqvi, Syeda Minahal Fatima, Syed Muhammad Waji-Ul-Hassan, Shakaib Arslan Gursal, Shazia Fatima, Muhammad Babar Imran, Mohammad Wasim, Mohamed Fawzy Ramadan, Nadeem Ahmed Lodhi Cancer Biotherapy and Radiopharmaceuticals.2026;[Epub] CrossRef